
Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease.

Journal: Open Forum Infect Dis

Publication Year: 2021

Authors: Michael J Peluso, Sadie E Munter, Kara L Lynch, Cassandra Yun, Leonel Torres, Nikita S Iyer, Joanna Donatelli, Lindsay Ryan, Amelia N Deitchman, Steven G Deeks, Rachel L Rutishauser, Timothy J Henrich

PubMed link: 34395717

Funding Grants: CIRM Bridges 2.0: Training the Next Generation of Stem Cell Scientists

Public Summary:

We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain-specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding anti-B-cell therapy for >7 months before vaccination. The patient developed virus-specific T-cell responses.

Scientific Abstract:

We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain-specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding anti-B-cell therapy for >7 months before vaccination. The patient developed virus-specific T-cell responses.

Source URL: <https://www.cirm.ca.gov/about-cirm/publications/discordant-virus-specific-antibody-levels-antibody-neutralization-capacity>